Seres Therapeutics Inc. ( (MCRB) ) has released its Q4 earnings. Here is a breakdown of the information Seres Therapeutics Inc. presented to its investors.
Seres Therapeutics, Inc. is a clinical-stage biotherapeutics company focused on developing live microbiome therapeutics to improve patient outcomes in medically vulnerable populations, particularly in the field of inflammatory and immune diseases. In its latest earnings report, Seres Therapeutics highlighted significant progress in its SER-155 program, a live biotherapeutic candidate designed to prevent bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The company received FDA Breakthrough Therapy designation for SER-155 and plans to submit a new study protocol to the FDA in Q2 2025.
The company’s financial performance for 2024 showed a net loss from continuing operations of $125.8 million, a significant improvement from the $190.1 million loss in 2023. This improvement was attributed to reduced research and development expenses and general administrative costs. Additionally, Seres reported a net income from discontinued operations of $125.9 million, primarily due to the sale of its VOWST business to Nestlé Health Science.
Key highlights from the report include the promising results from the SER-155 Phase 1b study, which demonstrated a 77% reduction in bloodstream infections compared to placebo. The company is also exploring broader applications for SER-155 and other biotherapeutic candidates in various medically vulnerable populations, including cancer patients and individuals with chronic liver disease.
Looking ahead, Seres Therapeutics is focused on advancing its SER-155 program and exploring strategic partnerships to maximize its clinical and commercial potential. With anticipated payments from Nestlé and current cash reserves, the company expects to fund operations into the first quarter of 2026.